Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy ( Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China )

Monitoring ovarian function in oncology studies

Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA

Monitoring ovarian function in oncology studies ( Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA )

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs...

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

Safety and quality of life assessment, how do they impact patient decision...

Prof Manuela Schmidinger and Dena Battle

Safety and quality of life assessment, how do they impact patient decision? KCCure survey – part B ( Prof Manuela Schmidinger and Dena Battle )

HER2DX assay and survival outcomes: An individual-patient level meta-analysis...

Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO)...

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

CAR-T, bispecifics or ADCs in late-stage RRMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy

CAR-T, bispecifics or ADCs in late-stage RRMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Complementing clinical trials: Investigating the value of real world evidence...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Treatment of multiple myeloma in Turkey

Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey

Treatment of multiple myeloma in Turkey ( Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey )

Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed...

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

$Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

Grand Rounds: Improving quality of patient-centred care

Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado

Grand Rounds: Improving quality of patient-centred care ( Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado )

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy...

Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer ( Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel )

More from ecancer